Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Kronox Lab Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 127.52 | 98.83 | 73.99 |
| Other Liabilities Total | 0.02 | 0.03 | 0.02 |
| Long Term Debt | 1 | Not available | Not available |
| Common Stock Total | 37.1 | 37.1 | 37.1 |
| Other Current Assets Total | 0.55 | 0.53 | 11.28 |
| Total Assets | 127.52 | 98.83 | 73.99 |
| Current Portof LT Debt/Capital Leases | 0 | Not available | 0 |
| Cash | 48.74 | 8.44 | 3.64 |
| Total Equity | 116.13 | 90.1 | 66.3 |
| Long Term Investments | 18.67 | 6.41 | 0.03 |
| Retained Earnings(Accumulated Deficit) | 79.02 | 52.49 | 28.88 |
| Total Common Shares Outstanding | 3.71 | 3.71 | 3.71 |
| Tangible Book Valueper Share Common Eq | 31.3 | 24.28 | 17.87 |
| Total Liabilities | 11.4 | 8.72 | 7.69 |
| Total Debt | 1.61 | 0 | 0 |
| Cashand Short Term Investments | 48.74 | 35.87 | 3.64 |
| Total Receivables Net | 21.19 | 20.44 | 22.37 |
| Notes Payable/Short Term Debt | 0.6 | 0 | 0 |
| Accounts Receivable-Trade Net | 21.19 | 20.17 | 18.28 |
| Property/Plant/Equipment Total-Net | 29.61 | 28.62 | 26.89 |
| Total Current Liabilities | 10.37 | 8.7 | 7.67 |
| Total Inventory | 8.37 | 6.37 | 9.25 |
| Accounts Payable | 6.58 | 7.28 | 6.24 |
| Other Currentliabilities Total | 3.18 | 1.42 | 1.43 |
| Total Long Term Debt | 1 | 0 | 0 |
| Other Long Term Assets Total | 0.4 | 0.5 | 0.48 |
| Total Current Assets | 78.84 | 63.31 | 46.6 |
| Accumulated Depreciation Total | Not available | -12.45 | -11.03 |
| Other Equity Total | Not available | 0.51 | 0.32 |
| Prepaid Expenses | Not available | 0.09 | 0.06 |
| Property/Plant/Equipment Total-Gross | Not available | 40.31 | 26.65 |
| Short Term Investments | Not available | 27.44 | Not available |
| Capital Lease Obligations | Not available | Not available | 0 |
PEG Ratio1.05
Price to Sale Ratio5.53
Debt 5Yr CAGR %-14.98
Operating Margin 12m31.72
Operating Margin 5y Avg27.53
Net Profit Margin 12m27.21
Net Profit Margin 5y22.28
Dividend Yield %0.33
Overall RiskHigh risk
Board Risk47.55
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,672.65 | 2.56 L | 58.09 | — |
| Solar Industries India | INR 18,915.1 | 1.71 L | 99.61 | — |
| Pidilite Industries | INR 1,577.3 | 1.61 L | 64.76 | — |
| SRF | INR 2,865.4 | 85,179.49 | 44.57 | — |
| Linde India | INR 6,897.45 | 58,824.36 | 110.53 | — |
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Kronox Lab Sciences Ltd is Rated Sell Markets Mojo
Kronox Lab FY26 Net Profit Rises, Declares Dividend scanx.trade
Kronox Lab Sciences standalone net profit rises 26.58% in the March 2026 quarter Business Standard
Kronox Lab Sciences Q4 FY26: Record Profitability Masks Growth Concerns Markets Mojo
Kronox Lab Scie Standalone March 2026 Net Sales at Rs 26.13 crore, down 0.02% Y-o-Y Moneycontrol.com
Kronox Lab Sciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 marketscreener.com
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Kronox Lab Sciences Limited is an India-based company engaged in the manufacturing of high purity fine, inorganic chemicals, phosphate and metallic chemicals. It is a bulk manufacturer of high purity fine chemicals for the pharmaceutical, nutraceutical, veterinary, food, chemical analysis and other specialty markets. The Company offers a line of chemicals including acetates, carbonates, chlorides, citrates, nitrates, nitrites, phosphates, sulfates, and ultrapure metallic salts. The Company’s product range includes ACS Reagent, LR, AR and GR Reagents, Oral Care, Pharmacopoeia, Food and Nutraceutical, Personal Care and Cosmetics, Veterinary Pharma and Animal Health, Tartrates, Citrates, Hypophosphites, Phosphates, Hydroxides, Ethylenediaminetetraacetic acid (EDTA) and Derivatives, Ultra High Purity Chemicals, Custom Specification, and Specialty Anhydrous. It manufactures high purity specialty fine chemicals of various grades in particle sizes ranging from 10 mesh to 100 mesh.
Kronox Lab Sciences has the symbol KRONOX and ISIN - INE0ATZ01017.
Kronox Lab Sciences is currently trading at INR 150.79.
Kronox Lab Sciences has a year high of INR 202.00 and a year low of INR 96.00.
Kronox Lab Sciences has a market capitalization of INR 559.45 crore.
Kronox Lab Sciences has a P/E ratio of 12.95.
Kronox Lab Sciences has a dividend yield of 0.33%.
Kronox Lab Sciences has revenue of INR 101.22 crore, net income of INR 27.66 crore, and EPS of INR 7.49.
Kronox Lab Sciences has a book value of INR 31.30.
Kronox Lab Sciences has a debt-to-equity ratio of NA.
Kronox Lab Sciences has a price-to-book ratio of 4.82 and a price-to-sales ratio of 5.53.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.